表紙:DTx (デジタルセラピューティクス) の世界市場 (~2026年):用途 (糖尿病予防・栄養・ケア・糖尿病・CVD・CNS・CRD・MSD・GI・薬物乱用・リハビリ)・販売経路 (B2C・患者・介護者・B2B・医療機関・保険者・雇用者・製薬企業)・地域別
市場調査レポート
商品コード
1019454

DTx (デジタルセラピューティクス) の世界市場 (~2026年):用途 (糖尿病予防・栄養・ケア・糖尿病・CVD・CNS・CRD・MSD・GI・薬物乱用・リハビリ)・販売経路 (B2C・患者・介護者・B2B・医療機関・保険者・雇用者・製薬企業)・地域別

Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma)-Global Forecasts to 2026

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 198 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円
DTx (デジタルセラピューティクス) の世界市場 (~2026年):用途 (糖尿病予防・栄養・ケア・糖尿病・CVD・CNS・CRD・MSD・GI・薬物乱用・リハビリ)・販売経路 (B2C・患者・介護者・B2B・医療機関・保険者・雇用者・製薬企業)・地域別
出版日: 2021年07月14日
発行: MarketsandMarkets
ページ情報: 英文 198 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のDTx (デジタルセラピューティクス) の市場規模は予測期間中31.4%のCAGRで推移し、2021年の34億米ドルから、2026年には131億米ドルの規模に成長すると予測されています。

予防可能な慢性疾患の発症率の増加、医療費抑制へのニーズ、予防医療への注目の高まり、DTxへの投資の増加などの要因が同市場の成長を推進しています。一方で、新興諸国におけるDTxプログラムへの認識やアクセスの不足、従来型の医療機関からの抵抗、不安定な決済モデルなどの課題が市場のさらなる成長を阻んでいます。

用途別では、治療・ケアの部門が2020年に最大のシェアを示しています。その中でも特に糖尿病の部門が2020年に19.0%と最大のシェアを示しています。糖尿病の有病率の増加、糖尿病に伴う高額な医療費、費用対効果の高いソリューションを用いて負担を軽減するための政府の取り組みの増加などの要因が同部門の成長を牽引しています。

当レポートでは、世界のDTx (デジタルセラピューティクス) の市場を調査し、市場の定義と概要、バリューチェーン、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、技術分析、パイプライン製品、ケーススタディ、市場規模の推移・予測、用途・販売経路・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターのファイブフォース分析
  • バリューチェーン分析
  • エコシステム
  • パイプライン製品
  • 技術動向
  • ケーススタディ
  • 規制状況
  • COVID-19の影響

第6章 市場分析・予測:用途別

  • 治療・ケア
    • 糖尿病
    • 中枢神経系障害
    • 禁煙
    • 慢性呼吸器疾患
    • 筋骨格系障害
    • 循環器疾患
    • 服薬遵守
    • 胃腸障害
    • リハビリテーション・患者ケア
    • 物質使用障害・依存症管理
    • その他
  • 予防
    • 糖尿病
    • 肥満
    • 栄養
    • ライフスタイル管理
    • その他

第7章 市場分析・予測:販売経路別

  • B2B
    • 保険者
    • 雇用者
    • 製薬企業
    • 医療機関
    • その他
  • B2C
    • 介護者
    • 患者

第8章 市場分析・予測:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第9章 競合情勢

  • 概要
  • 市場ランキング分析
  • 企業の評価マトリックス
  • 競合シナリオ

第10章 企業プロファイル

  • NOOM, INC.
  • LIVONGO HEALTH
  • OMADA HEALTH
  • COGNIFIT
  • WELLDOC
  • GINGER
  • PROPELLER HEALTH
  • 2MORROW, INC.
  • CANARY HEALTH
  • MANGO HEALTH, INC.
  • CLICK THERAPEUTICS
  • PEAR THERAPEUTICS
  • AKILI INTERACTIVE LABS, INC.
  • WELLTHY THERAPEUTICS
  • COGNOA, INC.
  • HAPPIFY
  • KAIA HEALTH
  • AYOGO HEALTH
  • BETTER THERAPEUTICS
  • MINDSTRONG HEALTH
  • BEHAVR INC.
  • MINDABLE HEALTH
  • VIRTA HEALTH
  • HINGE HEALTH
  • DOKTOR.SE

第11章 付録

目次
Product Code: HIT 4407

The global digital therapeutics market is projected to reach USD 13.1 billion by 2026 from USD 3.4billion in 2021, at a CAGR of 31.4%. Growth in this market is primarily driven by the increasing incidence of preventable chronic diseases, the need to control healthcare costs, rising focus on preventive healthcare, and rising investments in digital therapeutics. However, a lack of awareness and access to digital therapeutics programs in developing countries, resistance from traditional healthcare providers, and unstable payment models are challenging the growth of this market.

Treatment/care-related applications segment accounted for the largest share of the digital therapeutics market in 2020

Based on application, the digital therapeutics market is segmented into preventive and treatment/care-related applications. The large share of this segment is attributed to the growing incidences of chronic diseases, the rising economic burden of their treatment, and investments in digital therapeutics to encourage the development of cost-effective and scalable treatment platforms for these conditions.

Diabetes segment is expected to dominate the market

Based on the type of treatment/care-related application, the digital therapeutics market is further segmented into diabetes, CNS disorders, chronic respiratory diseases, musculoskeletal disorders, cardiovascular diseases, smoking cessation, medication adherence, gastrointestinal disorders, substance use disorders & addiction management, rehabilitation & patient care, and other treatment/care-related applications. Diabetes commanded the largest share of 19.0% of the digital therapeutics market for treatment/care-related applications in 2020. The growing prevalence of diabetes, high healthcare costs associated with diabetes, and increasing government initiatives to reduce the burden with the help of cost-effective solutions are expected to drive the market growth in this segment.

B2B segment is expected to grow at the highest CAGR during the forecast period.

Based on the sales channel, the digital therapeutics market is segmented into business-to-customer (B2C) and business-to-business (B2B). This is attributed to growing awareness among providers, payers, and employers about the benefits of digital therapeutics and the inclination of pharmaceutical companies to integrate digital therapeutics with their drug products.

North America to be the largest and the fastest-growing regional market

North America, which comprises the US and Canada, forms the largest market for digital therapeutics.Factors such as the influx of new startups, increasing investments in digital therapeutics, improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements drive market growth in this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 (50%), Tier 2 (30%), and Tier 3 (20%)
  • By Designation: C-level (75%), D-level (15%), and Others (10%)
  • By Region: North America (70%), Europe (20%), APAC (7%), and the RoW(3%)

List of Companies Profiled in the Report

  • Noom (US)
  • Livongo Health (US)
  • Omada Health (US)
  • WellDoc (US)
  • Pear Therapeutics (US)
  • Proteus Digital Health (US)
  • Propeller Health (US)
  • Akili Interactive Labs (US)
  • Better Therapeutics (US)
  • Happify (US)
  • Kaia Health (Germany)
  • Mango Health (US)
  • Click Therapeutics (US)
  • Canary Health (US)
  • Wellthy Therapeutics (India)
  • Cognoa (US)
  • Ayogo Health (Canada)
  • Mindstrong Health (US)
  • 2Morrow (US)
  • Ginger (US)
  • BehaVR Inc., (US)
  • Mindable Health (Germany)
  • Virta Health (US)
  • Hinge Health (US)
  • Doktor.se (Sweden)

Research Coverage:

This report provides a study of the digital therapeutics market. It aims at estimating the size and future growth potential of the market across different segments, such as sales channel, application, and region.The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall digital therapeutics market and its subsegments. This report will also help stakeholders understand the competitive landscape, gain insights to position their business,and make suitable go-to-market strategies. It will also enable stakeholders to gauge the pulse of the market and provide them with information on the key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
    • 1.2.2 MARKETS COVERED
    • 1.2.3 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 LIMITATIONS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
    • FIGURE 3 KEY INDUSTRY INSIGHTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY TYPE OF BUYER AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach one: revenue mapping-based estimation
    • FIGURE 6 ESTIMATION OF THE DIGITAL THERAPEUTICS MARKET: REVENUE MAPPING-BASED ESTIMATION
      • 2.2.1.2 Approach two: Buyer adoption-based estimation
    • FIGURE 7 MARKET SIZE ESTIMATION: BUYER ADOPTION-BASED ESTIMATION
    • 2.2.2 TOP-DOWN APPROACH: PENETRATION RATE-BASED MARKET SIZE ESTIMATION
    • FIGURE 8 PENETRATION RATE-BASED MARKET ESTIMATION
    • 2.2.3 GROWTH FORECAST
    • TABLE 1 FACTOR ANALYSIS
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET PLAYER RANKING
  • 2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

    • FIGURE 10 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021 VS. 2026 (USD MILLION)
    • FIGURE 11 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, 2021 VS. 2026 (USD MILLION)
    • FIGURE 12 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL: PAYERS HOLD THE LARGEST MARKET SHARE
    • FIGURE 13 DIGITAL THERAPEUTICS MARKET, BY APPLICATION (2021-2026)
    • FIGURE 14 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, 2021 VS. 2026 (USD MILLION)
    • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE DIGITAL THERAPEUTICS MARKET

4 PREMIUM INSIGHTS

  • 4.1 DIGITAL THERAPEUTICS MARKET OVERVIEW
    • FIGURE 16 INCREASING INCIDENCE OF CHRONIC DISEASES & TECHNOLOGICAL ADVANCEMENTS ARE DRIVING THE ADOPTION OF DIGITAL THERAPEUTICS
  • 4.2 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026
    • FIGURE 17 B2B SALES DOMINATE THE DIGITAL THERAPEUTICS MARKET
  • 4.3 DIGITAL THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 18 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR DIGITAL THERAPEUTICS

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 DIGITAL THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing incidence of preventable chronic diseases
      • 5.2.1.2 Rising focus on preventive healthcare
      • 5.2.1.3 Need to control healthcare costs
      • 5.2.1.4 Significant increase in venture capital investments
      • 5.2.1.5 Benefits of digital therapeutics
        • 5.2.1.5.1 Ability to induce behavioral change
        • 5.2.1.5.2 Improved drug adherence
        • 5.2.1.5.3 Patient convenience and user-friendliness
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Patient data privacy concerns
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging markets
      • 5.2.3.2 Large undiagnosed and untreated population
      • 5.2.3.3 Unexplored therapeutic applications
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Unstable payment models
      • 5.2.4.2 Reluctance among patients to adopt digital therapeutics
      • 5.2.4.3 Lack of awareness and access to digital therapeutics programs in developing countries
      • 5.2.4.4 Resistance from traditional healthcare providers
  • 5.3 PORTER'S FIVE FORCES ANALYSIS
    • 5.3.1 THREAT OF NEW ENTRANTS
    • 5.3.2 BARGAINING POWER OF SUPPLIERS
    • 5.3.3 BARGAINING POWER OF BUYERS
    • 5.3.4 THREAT OF SUBSTITUTES
    • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 20 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
    • FIGURE 21 ECOSYSTEM ANALYSIS
  • 5.6 PIPELINE PRODUCTS
  • 5.7 TECHNOLOGY TRENDS
  • 5.8 CASE STUDIES
  • 5.9 REGULATORY LANDSCAPE
    • TABLE 2 DIGITAL THERAPEUTICS MARKET: REGULATORY DATA NEEDED FOR CLASS II DEVICES
  • 5.10 IMPACT OF COVID-19 ON THE DIGITAL THERAPEUTICS MARKET

6 DIGITAL THERAPEUTICS MARKET, BY APPLICATION

  • 6.1 INTRODUCTION
    • TABLE 3 DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
  • 6.2 TREATMENT/CARE-RELATED APPLICATIONS
    • TABLE 4 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 5 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.1 DIABETES
      • 6.2.1.1 Rising prevalence of diabetes to drive market growth
    • TABLE 6 DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.2 CENTRAL NERVOUS SYSTEM DISORDERS
    • TABLE 7 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 8 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY REGION, 2019-2026 (USD MILLION)
      • 6.2.2.1 Mental health disorders
        • 6.2.2.1.1 Potential benefits of digital therapeutics in mental health disorder management have driven the development of these solutions
    • TABLE 9 DIGITAL THERAPEUTICS MARKET FOR MENTAL HEALTH DISORDERS, BY REGION, 2019-2026 (USD MILLION)
      • 6.2.2.2 Other CNS disorders
    • TABLE 10 DIGITAL THERAPEUTICS MARKET FOR OTHER CNS DISORDERS, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.3 SMOKING CESSATION
      • 6.2.3.1 Focus on providing clinically validated, effective mobile applications to help quit smoking to aid market growth
    • TABLE 11 DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.4 CHRONIC RESPIRATORY DISEASES
      • 6.2.4.1 Growing prevalence of COPD and asthma to drive market growth
    • TABLE 12 DIGITAL THERAPEUTICS MARKET FOR CHRONIC RESPIRATORY DISEASES, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.5 MUSCULOSKELETAL DISORDERS
      • 6.2.5.1 Dearth of physiotherapists to support market growth
    • TABLE 13 DIGITAL THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.6 CARDIOVASCULAR DISEASE
      • 6.2.6.1 High burden of CVD across the globe is the major factor driving the demand for digital therapeutics solutions
    • TABLE 14 DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.7 MEDICATION ADHERENCE
      • 6.2.7.1 Growing number of medication non-adherence cases to propel market growth
    • TABLE 15 DIGITAL THERAPEUTICS MARKET FOR MEDICATION ADHERENCE, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.8 GASTROINTESTINAL DISORDERS
      • 6.2.8.1 High prevalence of gastrointestinal disorders has attracted many startups in the space of digital health
    • TABLE 16 DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.9 REHABILITATION & PATIENT CARE
      • 6.2.9.1 Benefits of digital therapeutics have induced startups to develop platforms for patient care
    • TABLE 17 DIGITAL THERAPEUTICS MARKET FOR REHABILITATION & PATIENT CARE, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT
      • 6.2.10.1 Potential to improve the efficiency of behavioral interventions to drive market growth
    • TABLE 18 DIGITAL THERAPEUTICS MARKET FOR SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT, BY REGION, 2019-2026 (USD MILLION)
    • 6.2.11 OTHER TREATMENT/CARE-RELATED APPLICATIONS
    • TABLE 19 DIGITAL THERAPEUTICS MARKET FOR OTHER TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2019-2026 (USD MILLION)
  • 6.3 PREVENTIVE APPLICATIONS
    • TABLE 20 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 21 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY REGION, 2019-2026 (USD MILLION)
    • 6.3.1 PREDIABETES
      • 6.3.1.1 Influx of startups to provide effective prevention against prediabetes will support market growth
    • TABLE 22 DIGITAL THERAPEUTICS MARKET FOR PREDIABETES, BY REGION, 2019-2026 (USD MILLION)
    • 6.3.2 OBESITY
      • 6.3.2.1 Availability of cost-effective solutions for obesity management to propel market growth
    • TABLE 23 DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY REGION, 2019-2026 (USD MILLION)
    • 6.3.3 NUTRITION
      • 6.3.3.1 Importance of nutrition in preventing a wide range of ailments has driven the demand for digital therapeutic solutions
    • TABLE 24 DIGITAL THERAPEUTICS MARKET FOR NUTRITION, BY REGION, 2019-2026 (USD MILLION)
    • 6.3.4 LIFESTYLE MANAGEMENT
      • 6.3.4.1 Ability of digital therapeutics solutions to induce positive behavioral changes has contributed to the rising demand
    • TABLE 25 DIGITAL THERAPEUTICS MARKET FOR LIFESTYLE MANAGEMENT, BY REGION, 2019-2026 (USD MILLION)
    • 6.3.5 OTHER PREVENTIVE APPLICATIONS
    • TABLE 26 DIGITAL THERAPEUTICS MARKET FOR OTHER PREVENTIVE APPLICATIONS, BY REGION, 2019-2026 (USD MILLION)

7 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL

  • 7.1 INTRODUCTION
    • TABLE 27 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
  • 7.2 B2B
    • TABLE 28 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 29 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY REGION, 2019-2026 (USD MILLION)
    • 7.2.1 PAYERS
      • 7.2.1.1 Payers held the largest market share
    • TABLE 30 DIGITAL THERAPEUTICS MARKET FOR PAYERS, BY REGION, 2019-2026 (USD MILLION)
    • 7.2.2 EMPLOYERS
      • 7.2.2.1 Importance of employee health management has increased the adoption of digital therapeutics among employers
    • TABLE 31 DIGITAL THERAPEUTICS MARKET FOR EMPLOYERS, BY REGION, 2019-2026 (USD MILLION)
    • 7.2.3 PHARMACEUTICAL COMPANIES
      • 7.2.3.1 Growing cross-industry collaborations between digital therapeutics start-ups and pharmaceutical companies to drive market growth
    • TABLE 32 DIGITAL THERAPEUTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2019-2026 (USD MILLION)
    • 7.2.4 PROVIDERS
      • 7.2.4.1 Potential for better patient management and cost-reductions are driving the demand for digital therapeutics among providers
    • TABLE 33 DIGITAL THERAPEUTICS MARKET FOR PROVIDERS, BY REGION, 2019-2026 (USD MILLION)
    • 7.2.5 OTHER BUYERS
    • TABLE 34 DIGITAL THERAPEUTICS MARKET FOR OTHER BUYERS, BY REGION, 2019-2026 (USD MILLION)
  • 7.3 B2C
    • TABLE 35 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 36 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY REGION, 2019-2026 (USD MILLION)
    • 7.3.1 CAREGIVERS
      • 7.3.1.1 Ease of managing health conditions has driven the demand for solutions among caregivers
    • TABLE 37 DIGITAL THERAPEUTICS MARKET FOR CAREGIVERS, BY REGION, 2019-2026 (USD MILLION)
    • 7.3.2 PATIENTS
      • 7.3.2.1 Awareness about preventive health among patients to support the growth of this segment
    • TABLE 38 DIGITAL THERAPEUTICS MARKET FOR PATIENTS, BY REGION, 2019-2026 (USD MILLION)

8 DIGITAL THERAPEUTICS MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 39 DIGITAL THERAPEUTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 8.2 NORTH AMERICA
    • FIGURE 22 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET SNAPSHOT
    • TABLE 40 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 41 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 42 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 43 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 44 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 45 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 46 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 47 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • 8.2.1 US
      • 8.2.1.1 Major digital therapeutics start-ups are based out of the US, which has greatly supported access to solutions
    • TABLE 48 US: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 49 US: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 50 US: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 51 US: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 52 US: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 53 US: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 54 US: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • 8.2.2 CANADA
      • 8.2.2.1 Government initiatives to support digital therapeutics to drive market growth in Canada
    • TABLE 55 CANADA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 56 CANADA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 57 CANADA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 58 CANADA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 59 CANADA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 60 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 61 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
  • 8.3 EUROPE
    • FIGURE 23 EUROPE: DIGITAL THERAPEUTICS MARKET SNAPSHOT
    • TABLE 62 EUROPE: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 63 EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 64 EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 65 EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 66 EUROPE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 67 EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 68 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 69 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • 8.3.1 GERMANY
      • 8.3.1.1 Germany is the largest market for digital therapeutics in Europe due to increasing government initiatives
    • TABLE 70 GERMANY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 71 GERMANY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 72 GERMANY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 73 GERMANY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 74 GERMANY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 75 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 76 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • 8.3.2 UK
      • 8.3.2.1 Well-established healthcare system and government support will propel the growth of the market
    • TABLE 77 UK: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 78 UK: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 79 UK: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 80 UK: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 81 UK: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 82 UK: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 83 UK: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • 8.3.3 FRANCE
      • 8.3.3.1 Growing healthcare expenditure and favorable health insurance system to support market growth in France
    • TABLE 84 FRANCE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 85 FRANCE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 86 FRANCE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 87 FRANCE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 88 FRANCE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 89 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 90 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • 8.3.4 SPAIN
      • 8.3.4.1 Initiatives by emerging digital therapeutics startups are supporting market growth
    • TABLE 91 SPAIN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 92 SPAIN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 93 SPAIN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 94 SPAIN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 95 SPAIN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 96 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 97 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • 8.3.5 ITALY
      • 8.3.5.1 Need for alternative and effective treatment to drive the market growth in the coming years
    • TABLE 98 ITALY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 99 ITALY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 100 ITALY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 101 ITALY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 102 ITALY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 103 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 104 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • 8.3.6 REST OF EUROPE
    • TABLE 105 ROE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 106 ROE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 107 ROE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 108 ROE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 109 ROE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 110 ROE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 111 ROE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • TABLE 112 APAC: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 113 APAC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 114 APAC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 115 APAC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 116 APAC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 117 APAC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 118 APAC: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 119 APAC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • 8.4.1 JAPAN
      • 8.4.1.1 Rising diabetes incidence and collaborations between stakeholders are indicators of market growth in Japan
    • TABLE 120 JAPAN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 121 JAPAN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 122 JAPAN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 123 JAPAN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 124 JAPAN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 125 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 126 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • 8.4.2 CHINA
      • 8.4.2.1 The growing geriatric population and incidence of chronic conditions will drive demand for digital therapeutics in China
    • TABLE 127 CHINA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 128 CHINA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 129 CHINA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 130 CHINA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 131 CHINA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 132 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 133 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • 8.4.3 INDIA
      • 8.4.3.1 Rising chronic disease incidence and the need for better disease management drive market growth
    • TABLE 134 INDIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 135 INDIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 136 INDIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 137 INDIA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 138 INDIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 139 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 140 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • 8.4.4 REST OF APAC
    • TABLE 141 ROAPAC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 142 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 143 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 144 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 145 ROAPAC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 146 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 147 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
  • 8.5 REST OF THE WORLD
    • TABLE 148 ROW: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 149 ROW: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 150 ROW: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 151 ROW: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 152 ROW: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019-2026 (USD MILLION)
    • TABLE 153 ROW: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)
    • TABLE 154 ROW: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019-2026 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
    • FIGURE 24 KEY PLAYERS ADOPTED ORGANIC AS WELL AS INORGANIC GROWTH STRATEGIES BETWEEN 2016 AND 2021
  • 9.2 MARKET RANKING ANALYSIS, 2021
    • FIGURE 25 DIGITAL THERAPEUTICS MARKET RANKING ANALYSIS, 2021
  • 9.3 COMPANY EVALUATION MATRIX
    • 9.3.1 INTRODUCTION
    • 9.3.2 COMPANY EVALUATION MATRIX: DEFINITIONS AND METHODOLOGY
      • 9.3.2.1 Stars
      • 9.3.2.2 Emerging leaders
      • 9.3.2.3 Pervasive players
      • 9.3.2.4 Emerging companies
    • FIGURE 26 DIGITAL THERAPEUTICS MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2021
    • 9.3.3 COMPETITIVE LEADERSHIP MAPPING: START-UPS/SMES (2021)
      • 9.3.3.1 Progressive companies
      • 9.3.3.2 Starting blocks
      • 9.3.3.3 Responsive companies
      • 9.3.3.4 Dynamic companies
    • FIGURE 27 DIGITAL THERAPEUTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
  • 9.4 COMPETITIVE SCENARIO
    • 9.4.1 DEALS
    • TABLE 155 DIGITAL THERAPEUTICS MARKET: DEALS, JANUARY 2016 TO JUNE 2021
    • 9.4.2 PRODUCT LAUNCHES
    • TABLE 156 DIGITAL THERAPEUTICS MARKET: PRODUCT LAUNCHES, JANUARY 2016 TO JUNE 2021
    • 9.4.3 EXPANSIONS
    • TABLE 157 DIGITAL THERAPEUTICS MARKET: EXPANSIONS, JANUARY 2016 TO JUNE 2021

10 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, MnM View)**
  • 10.1 NOOM, INC.
  • 10.2 LIVONGO HEALTH
  • 10.3 OMADA HEALTH
  • 10.4 COGNIFIT
  • 10.5 WELLDOC
  • 10.6 GINGER
  • 10.7 PROPELLER HEALTH
  • 10.8 2MORROW, INC.
  • 10.9 CANARY HEALTH
  • 10.10 MANGO HEALTH, INC.
  • 10.11 CLICK THERAPEUTICS
  • 10.12 PEAR THERAPEUTICS
  • 10.13 AKILI INTERACTIVE LABS, INC.
  • 10.14 WELLTHY THERAPEUTICS
  • 10.15 COGNOA, INC.
  • 10.16 HAPPIFY
  • 10.17 KAIA HEALTH
  • 10.18 AYOGO HEALTH
  • 10.19 BETTER THERAPEUTICS
  • 10.20 MINDSTRONG HEALTH
  • 10.21 BEHAVR INC.
  • 10.22 MINDABLE HEALTH
  • 10.23 VIRTA HEALTH
  • 10.24 HINGE HEALTH
  • 10.25 DOKTOR.SE
  • *Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 AVAILABLE CUSTOMIZATIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS